메뉴 건너뛰기




Volumn 5, Issue 9, 2006, Pages 2281-2288

Intracellular inhibition of carboxylesterases by benzil: Modulation of CPT-11 cytotoxicity

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLORO N [4 [[(4 CHLOROPHENYL)SULFONYL]AMINO]PHENYL]BENZENESULFONAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BENZIL; CARBOXYLESTERASE; CYTOTOXIC AGENT; HYMECROMONE; IRINOTECAN; UNCLASSIFIED DRUG;

EID: 33749556946     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0160     Document Type: Article
Times cited : (41)

References (35)
  • 2
    • 0031800635 scopus 로고    scopus 로고
    • The mammalian carboxylesterases: From molecules to function
    • Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to function. Annu Rev Pharmacol Toxicol 1998;38:257-88.
    • (1998) Annu Rev Pharmacol Toxicol , vol.38 , pp. 257-288
    • Satoh, T.1    Hosokawa, M.2
  • 4
    • 0032929154 scopus 로고    scopus 로고
    • Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy
    • Danks MK, Morton CL, Krull EJ, et al. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 1999;5:917-24.
    • (1999) Clin Cancer Res , vol.5 , pp. 917-924
    • Danks, M.K.1    Morton, C.L.2    Krull, E.J.3
  • 5
    • 0034282809 scopus 로고    scopus 로고
    • Proficient metabolism of CPT-11 by a human intestinal carboxylesterase
    • Khanna R, Morton CL, Danks MK, Potter PM. Proficient metabolism of CPT-11 by a human intestinal carboxylesterase. Cancer Res 2000;60: 4725-8.
    • (2000) Cancer Res , vol.60 , pp. 4725-4728
    • Khanna, R.1    Morton, C.L.2    Danks, M.K.3    Potter, P.M.4
  • 6
    • 0033870254 scopus 로고    scopus 로고
    • Activation of CPT-11 in mice: Identification and analysis of a highly effective plasma esterase
    • Morton CL, Wierdl M, Oliver L, et al. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res 2000;60:4206-10.
    • (2000) Cancer Res , vol.60 , pp. 4206-4210
    • Morton, C.L.1    Wierdl, M.2    Oliver, L.3
  • 7
    • 0032526239 scopus 로고    scopus 로고
    • Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11)
    • Potter PM, Pawlik CA, Morton CL, Naeve CW, Danks MK. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res 1998;52: 2646-51.
    • (1998) Cancer Res , vol.52 , pp. 2646-2651
    • Potter, P.M.1    Pawlik, C.A.2    Morton, C.L.3    Naeve, C.W.4    Danks, M.K.5
  • 8
    • 0028364014 scopus 로고
    • Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase
    • Satoh T, Hosokawa M, Atsumi R, et al. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994;17:662-4.
    • (1994) Biol Pharm Bull , vol.17 , pp. 662-664
    • Satoh, T.1    Hosokawa, M.2    Atsumi, R.3
  • 9
    • 0035392963 scopus 로고    scopus 로고
    • Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase
    • Wierdl M, Morton CL, Weeks JK, et al. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 2001;61:5078-82.
    • (2001) Cancer Res , vol.61 , pp. 5078-5082
    • Wierdl, M.1    Morton, C.L.2    Weeks, J.K.3
  • 10
    • 0027324850 scopus 로고
    • Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin
    • Houghton PJ, Cheshire PJ, Hallman JC, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993;53:2823-39.
    • (1993) Cancer Res , vol.53 , pp. 2823-2839
    • Houghton, P.J.1    Cheshire, P.J.2    Hallman, J.C.3
  • 11
    • 0029116438 scopus 로고
    • Efficacy of topoisomerase I inhibitors, topotecan, and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
    • Houghton PJ, Cheshire PJ, Hallman JD II, et al. Efficacy of topoisomerase I inhibitors, topotecan, and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
    • (1995) Cancer Chemother Pharmacol , vol.36 , pp. 393-403
    • Houghton, P.J.1    Cheshire, P.J.2    Hallman II, J.D.3
  • 12
    • 0029165929 scopus 로고
    • Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan
    • Bonneterre J. Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan. Bull Cancer 1995;82:623-8.
    • (1995) Bull Cancer , vol.82 , pp. 623-628
    • Bonneterre, J.1
  • 13
    • 0000148072 scopus 로고
    • Efficacy of irinotecan HCI (CPT11) in patients with metastatic colorectal cancer after progression while receiving a 5-FU-based chemotherapy
    • Bugat R, Rougier P, Douillard JY, et al. Efficacy of irinotecan HCI (CPT11) in patients with metastatic colorectal cancer after progression while receiving a 5-FU-based chemotherapy. Proc Am Soc Clin Oncol Annu Meet 1995;14:A567.
    • (1995) Proc Am Soc Clin Oncol Annu Meet , vol.14
    • Bugat, R.1    Rougier, P.2    Douillard, J.Y.3
  • 14
    • 0029919598 scopus 로고    scopus 로고
    • Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
    • Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:709-15.
    • (1996) J Clin Oncol , vol.14 , pp. 709-715
    • Conti, J.A.1    Kemeny, N.E.2    Saltz, L.B.3
  • 15
    • 0029964872 scopus 로고    scopus 로고
    • Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation
    • Cunningham D. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Eur J Cancer 1996;32A Suppl 3:S1-8.
    • (1996) Eur J Cancer , vol.32 A , Issue.SUPPL. 3
    • Cunningham, D.1
  • 17
    • 0842308823 scopus 로고    scopus 로고
    • Progress in treatment of small-cell lung cancer: Role of CPT-11
    • Saijo N. Progress in treatment of small-cell lung cancer: role of CPT-11. Br J Cancer 2003;89:2178-83.
    • (2003) Br J Cancer , vol.89 , pp. 2178-2183
    • Saijo, N.1
  • 18
    • 0033039308 scopus 로고    scopus 로고
    • Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children
    • Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-24.
    • (1999) J Clin Oncol , vol.17 , pp. 1815-1824
    • Furman, W.L.1    Stewart, C.F.2    Poquette, C.A.3
  • 19
    • 0029857839 scopus 로고    scopus 로고
    • Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies
    • Armand JP, Extra YM, Catimel G, et al. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 1996;7:837-42.
    • (1996) Ann Oncol , vol.7 , pp. 837-842
    • Armand, J.P.1    Extra, Y.M.2    Catimel, G.3
  • 20
    • 0000291599 scopus 로고    scopus 로고
    • A phase I trial to evaluate orally administered irinotecan HCL (CPT-11) given daily x 5 every 3 weeks in patients with refractory malignancies
    • Drengler R, Burris H, Dietz A, et al. A phase I trial to evaluate orally administered irinotecan HCL (CPT-11) given daily x 5 every 3 weeks in patients with refractory malignancies. Proc Am Soc Clin Oncol Annu Meet 1996;15:A1560.
    • (1996) Proc Am Soc Clin Oncol Annu Meet , vol.15
    • Drengler, R.1    Burris, H.2    Dietz, A.3
  • 21
    • 0011805038 scopus 로고
    • Phase I trial of irinotecan (CPT-11), 5-fluorouracil (FU), and leucovorin (LV) in patients with advanced solid tumors
    • Saltz L, Kanowitz J, Kemeny N, et al. Phase I trial of irinotecan (CPT-11), 5-fluorouracil (FU), and leucovorin (LV) in patients with advanced solid tumors. Proc Am Soc Clin Oncol Annu Meet 1995;14:A1546.
    • (1995) Proc Am Soc Clin Oncol Annu Meet , vol.14
    • Saltz, L.1    Kanowitz, J.2    Kemeny, N.3
  • 22
  • 24
    • 26444585076 scopus 로고    scopus 로고
    • Metabolism and antitumor activity of CPT-11 in plasma esterase-deficient mice
    • Morton CL, Iacono L, Hyatt JL, et al. Metabolism and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol 2005;56:629-36.
    • (2005) Cancer Chemother Pharmacol , vol.56 , pp. 629-636
    • Morton, C.L.1    Iacono, L.2    Hyatt, J.L.3
  • 25
    • 2442679029 scopus 로고    scopus 로고
    • Identification of novel selective human intestinal carboxylesterase inhibitors for the amelioration of irinotecan-induced diarrhea: Synthesis, quantitative structure-activity relationship analysis, and biological activity
    • Wadkins RM, Hyatt JL, Yoon KJ, et al. Identification of novel selective human intestinal carboxylesterase inhibitors for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol 2004;65: 1336-43.
    • (2004) Mol Pharmacol , vol.65 , pp. 1336-1343
    • Wadkins, R.M.1    Hyatt, J.L.2    Yoon, K.J.3
  • 26
    • 20944443990 scopus 로고    scopus 로고
    • Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases
    • Wadkins RM, Hyatt JL, Wei X, et al. Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem 2005;48:2905-15.
    • (2005) J Med Chem , vol.48 , pp. 2905-2915
    • Wadkins, R.M.1    Hyatt, J.L.2    Wei, X.3
  • 27
    • 0016365032 scopus 로고
    • Analytical study of microsomes and isolated subcellular membranes from rat liver. I. Biochemical methods
    • Beaufay H, Amar-Costesec A, Feytmans E, et al. Analytical study of microsomes and isolated subcellular membranes from rat liver. I. Biochemical methods. J Cell Biol 1974;61:188-200.
    • (1974) J Cell Biol , vol.61 , pp. 188-200
    • Beaufay, H.1    Amar-Costesec, A.2    Feytmans, E.3
  • 28
    • 0031557664 scopus 로고    scopus 로고
    • Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver
    • Schwer H, Langmann T, Daig R, et al. Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. Biochem Biophys Res Commun 1997;233:117-20.
    • (1997) Biochem Biophys Res Commun , vol.233 , pp. 117-120
    • Schwer, H.1    Langmann, T.2    Daig, R.3
  • 29
    • 0032440452 scopus 로고    scopus 로고
    • Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase
    • Guichard S, Morton CL, Krull EJ, et al. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. Clin Cancer Res 1998;4:3089-94.
    • (1998) Clin Cancer Res , vol.4 , pp. 3089-3094
    • Guichard, S.1    Morton, C.L.2    Krull, E.J.3
  • 30
    • 0031975059 scopus 로고    scopus 로고
    • Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11
    • Danks MK, Morton CL, Pawlik CA, Potter PM. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res 1998;58:20-2.
    • (1998) Cancer Res , vol.58 , pp. 20-22
    • Danks, M.K.1    Morton, C.L.2    Pawlik, C.A.3    Potter, P.M.4
  • 31
    • 23944470597 scopus 로고    scopus 로고
    • Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety
    • Hyatt JL, Stacy V, Wadkins RM, et al. Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety. J Med Chem 2005;48:5543-50.
    • (2005) J Med Chem , vol.48 , pp. 5543-5550
    • Hyatt, J.L.1    Stacy, V.2    Wadkins, R.M.3
  • 32
    • 29744447165 scopus 로고    scopus 로고
    • Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan
    • Ando M, Hasegawa Y, Ando Y. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Invest New Drugs 2005;23:539-45.
    • (2005) Invest New Drugs , vol.23 , pp. 539-545
    • Ando, M.1    Hasegawa, Y.2    Ando, Y.3
  • 33
    • 0029741368 scopus 로고    scopus 로고
    • Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
    • Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996;56:3752-7.
    • (1996) Cancer Res , vol.56 , pp. 3752-3757
    • Takasuna, K.1    Hagiwara, T.2    Hirohashi, M.3
  • 34
    • 33644841966 scopus 로고    scopus 로고
    • Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors
    • Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 2006;24:563-70.
    • (2006) J Clin Oncol , vol.24 , pp. 563-570
    • Furman, W.L.1    Crews, K.R.2    Billups, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.